Page 46 - Risk Evaluation News Today

-- In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response (CR+CRi 71%) and a Median Overall Survival of 26 Months

-- In Three-Year Follow-up in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, Tecartus Shows High Rates of Durable Response and a Median Overall Survival of 26 Months -- ... | February 9, 2023

On January 4, the Food and Drug Administration (FDA) approved modifications to the Risk Evaluation and Mitigation Strategies (REMS) program for the medication abortion drug...

The attorneys general in 20 states are responding to an FDA decision to make a pandemic era change permanent but the change doesn't affect Ohio anyway.

A change from the Federal Drug Administration won't likely have any impact on people seeking abortion pills here in Ohio.

The attorneys general in 20 states are responding to an FDA decision to make a pandemic era change permanent but the change doesn't affect Ohio anyway.

Below is Alston & Bird’s Health Care Week in Review, which provides a synopsis of the latest news in health care regulations, notices, and guidance; federal legislation and...

This Viewpoint summarizes several federal strategies to ensure pregnant persons’ access to abortion services after the recent Supreme Court ruling in Dobbs v Ja

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI®...

Though the anti-abortion movement notched a historic victory in the overturning of Roe v. Wade, it now faces a landscape where the medications collectively known as “the abortion pill” are increasingly accessible.